Vertex triple combinations
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Vertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound with its tezacaftor + ivacaftor backbone, which is now approved as Symdeko. New CFTR correctors evaluated so far include VX-152, VX-440, VX-445, and VX-659, with Vertex targeting VX-445 and VX-659 for further development.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Vertex triple combination program : Cystic fibrosis
LIST OF FIGURES
13 Figure 1: Vertex triple combination program for cystic fibrosis – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Vertex triple combination program for cystic fibrosis
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Vertex triple combination program for cystic fibrosis
17 Figure 4: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Vertex triple combination program drug profile
7 Table 2: Vertex triple combination program Phase II data in cystic fibrosis
11 Table 3: Vertex triple combination program Phase III data in cystic fibrosis
18 Table 4: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Quinsair 
Sign up to the